

Programme
IQWiG in Dialogue
12. Juni 2015

„How confirmatory is HTA?“

Host: Prof. Dr. Ralf Bender

10.00 - 10.15	Introduction Prof. Dr. Ralf Bender, IQWiG
10.15 - 10.45	HTA meets EMA – Methodological areas of debate from an industry point of view Dr. Claudia Nicolay, Eli Lilly & Friedhelm Leverkus, Pfizer
10.45 - 11.15	The regulatory process between confirmatory studies and benefit-risk assessment Dr. Jan Müller-Berghaus, Paul-Ehrlich-Institut, PEI
11.15 - 12.00	Discussion
12.00 - 13.00	Lunch break
13.00 - 13.30	Decision strategies in approval and benefit assessment from a biometric point of view Prof. Dr. Armin Koch & Yvonne Ziert, Hannover Medical School
13.30 - 14.15	How reliable are HTA decisions based on single RCTs? Prof. Dr. Gerald Gartlehner, Danube University Krems, Austria
14.15 - 14.30	Summary PD Dr. Stefan Lange, IQWiG
14.30 - 15.30	Discussion
15.30 - 16.00	Conclusion of the event with coffee and cake

Please note: the presentations are in German. The programme and abstracts are also provided in English as a service to English-language readers.

Location: KOMED, Im Mediapark 6 - Haus 6, D-50670 Köln